| Brachytherapy and bivalirudin evaluation study. | |
| | |
MedLine Citation:
|
PMID: 16209990 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Bivalirudin is shown to be a competent substitute for heparin in percutaneous coronary intervention (PCI). The safety and efficacy of bivalirudin in patients undergoing PCI and vascular brachytherapy (VBT) are not known. This study aimed to assess the safety and efficacy of bivalirudin as a single antithrombotic agent in patients undergoing PCI and VBT. METHODS: A total of 152 patients enrolled in the Brachytherapy and Bivalirudin Evaluation Study underwent PCI and VBT with either gamma (n = 8) or beta radiation (n = 144). The main outcome measures were in-hospital events and 30-day clinical outcomes. All patients were treated with bivalirudin (0.75 mg/kg bolus and 1.75 mg/kg per hour infusion for beta radiation, 1 mg/kg bolus and 2.5 mg/kg per hour infusion for gamma radiation) as a single antithrombotic agent during the entire procedure. RESULTS: Baseline clinical and angiographic characteristics were similar between the 2 groups. More than 90% of the patients received beta radiation. In-hospital events showed a higher prevalence of acute procedural intracoronary thrombosis in patients treated with gamma- vs beta radiation (25% vs. 0.7%, P < .001). Thirty-day outcomes including death, Q-wave, and non-Q-wave myocardial infarctions, subacute stent thromboses, and repeat revascularizations were similar in both groups. CONCLUSION: Bivalirudin, as a single antithrombotic agent during PCI and VBT with beta emitters, may be used safely, but its use in the setting of PCI and gamma radiation may not be acceptable due to an increased incidence of acute procedural intracoronary thrombosis. |
| | |
Authors:
|
Pramod Kuchulakanti; Roswitha Wolfram; Rebecca Torguson; Seung-Woon Rha; Edouard Cheneau; Ellen E Pinnow; Daniel Canos; Lowell F Satler; Augusto D Pichard; Kenneth M Kent; Ron Waksman |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American heart journal Volume: 150 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2005 Oct |
Date Detail:
|
Created Date: 2005-10-07 Completed Date: 2005-11-28 Revised Date: 2006-02-27 |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: 832-7 Citation Subset: AIM; IM |
Affiliation:
|
Division of Cardiology, Department of Internal Medicine, Washington Hospital Center, Washington, DC 20010, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Transluminal, Percutaneous Coronary*
/
adverse effects Anticoagulants / therapeutic use* Brachytherapy / adverse effects* Coronary Stenosis / radiotherapy*, therapy Female Hirudins Humans Male Middle Aged Peptide Fragments / therapeutic use* Recombinant Proteins / therapeutic use Thrombosis / etiology, prevention & control* |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Hirudins; 0/Peptide Fragments; 0/Recombinant Proteins; 128270-60-0/bivalirudin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Preprocedural Thrombolysis in Myocardial Infarction (TIMI) flow significantly affects the extent of ...
Next Document: Decade-long changes in the use of combination evidence-based medical therapy at discharge for patien...